Motor dysfunctions and neuropathology in mouse models of spinocerebellar ataxia type 2: A comprehensive review by Alves-Cruzeiro, João M. da Conceição et al.
MINI REVIEW
published: 15 December 2016
doi: 10.3389/fnins.2016.00572
Frontiers in Neuroscience | www.frontiersin.org 1 December 2016 | Volume 10 | Article 572
Edited by:
Tibor Hortobágyi,
University of Debrecen, Hungary
Reviewed by:
Anthony John Hannan,
Florey Institute of Neuroscience and
Mental Health, Australia
Terence Y. Pang,
Florey Institute of Neuroscience and
Mental Health, Australia
*Correspondence:
Clévio Nóbrega
cdnobrega@ualg.pt
Specialty section:
This article was submitted to
Neurodegeneration,
a section of the journal
Frontiers in Neuroscience
Received: 12 August 2016
Accepted: 28 November 2016
Published: 15 December 2016
Citation:
Alves-Cruzeiro JMDC, Mendonça L,
Pereira de Almeida L and Nóbrega C
(2016) Motor Dysfunctions and
Neuropathology in Mouse Models of
Spinocerebellar Ataxia Type 2: A
Comprehensive Review.
Front. Neurosci. 10:572.
doi: 10.3389/fnins.2016.00572
Motor Dysfunctions and
Neuropathology in Mouse Models of
Spinocerebellar Ataxia Type 2: A
Comprehensive Review
João M. Da Conceição Alves-Cruzeiro 1, Liliana Mendonça 1, Luís Pereira de Almeida 1, 2
and Clévio Nóbrega 3*
1Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal, 2 Faculty of Pharmacy, University of
Coimbra, Coimbra, Portugal, 3Department of Biomedical Sciences and Medicine and Center for Biomedical Research,
University of Algarve, Faro, Portugal
Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant ataxia caused by
an expansion of CAG repeats in the exon 1 of the gene ATXN2, conferring a gain
of toxic function that triggers the appearance of the disease phenotype. SCA2 is
characterized by several symptoms including progressive gait ataxia and dysarthria, slow
saccadic eye movements, sleep disturbances, cognitive impairments, and psychological
dysfunctions such as insomnia and depression, among others. The available treatments
rely on palliative care, which mitigate some of the major symptoms but ultimately fail
to block the disease progression. This persistent lack of effective therapies led to the
development of several models in yeast, C. elegans, D. melanogaster, and mice to
serve as platforms for testing new therapeutic strategies and to accelerate the research
on the complex disease mechanisms. In this work, we review 4 transgenic and 1
knock-in mouse that exhibit a SCA2-related phenotype and discuss their usefulness in
addressing different scientific problems. The knock-in mice are extremely faithful to the
human disease, with late onset of symptoms and physiological levels of mutant ataxin-2,
while the other transgenic possess robust and well-characterized motor impairments
and neuropathological features. Furthermore, a new BAC model of SCA2 shows
promise to study the recently explored role of non-coding RNAs as a major pathogenic
mechanism in this devastating disorder. Focusing on specific aspects of the behavior and
neuropathology, as well as technical aspects, we provide a highly practical description
and comparison of all the models with the purpose of creating a useful resource for SCA2
researchers worldwide.
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INTRODUCTION
Spinocerebellar ataxia type 2 (SCA2) belongs to a group of hereditary neurodegenerative diseases—
Polyglutamine (PolyQ) diseases—such as Huntington’s disease (HD), Spinal bulbar muscular
atrophy (SBMA), and several spinocerebellar ataxias (SCAs) (Fan et al., 2014). These disorders
share a common biological cause: an abnormal repetition of CAG triplets in the open reading
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frame of the causative genes. These triplet expansions encode
for an expanded polyglutamine tract in the respective proteins,
conferring a gain-of-function mutation that triggers the
appearance of the disease phenotype (Shao and Diamond, 2007;
Fan et al., 2014). In SCA2 patients, this expansion is found in
the exon 1 of the gene ATXN2, with a number of CAG repeats
above 31 (that can go up to 200), while the healthy individuals
usually possess between 13 and 31 repetitions (Magaña et al.,
2013). This neurodegenerative disorder was first known as
Wadia–Swami type ataxia owed to the two Indian researchers
that first reported it (Wadia and Swami, 1971; Sinha, 2004). Later
on, it became known as SCA2, after the discovery of the disease
locus in chromosome 12 (Gispert et al., 1993). The study of this
disease assumes a central relevance in Hispano-American and
Indian populations, since it has been demonstrated to be the
most prevalent form of ataxia in Mexico, Holguín (Cuba) and
eastern India (Sinha, 2004; Alonso et al., 2007; Velázquez-Pérez
et al., 2011). However, the existence of large SCA2 families has
also been reported in the UK (Leggo et al., 1997; Giunti et al.,
1998) and Spain (Pujana et al., 1999; Infante et al., 2005), where
it is probably the most common SCA, and many other countries
such as Australia, Germany, Italy, and Brazil. Worldwide, it
is considered the second most common form of autosomal
dominant cerebellar ataxia, together with SCA6, with 15% of
total cases (Lastres-Becker et al., 2008b; Magaña et al., 2013).
Before the identification of the ATXN2 mutation by three
different groups (Imbert et al., 1996; Pulst et al., 1996; Sanpei
et al., 1996), the diagnosis of this disease was based on
observations of its major symptoms, which have little variation
to the other SCAs. Thereby, SCA2 clinical manifestations include
a slow and progressive gait ataxia and dysarthria accompanied
by leg cramps, postural tremors, decreased muscle tone, and
decreased tendon reflexes (Pulst, 2015). These most often come
together with sleep disturbances and oculomotor dysfunctions
such as slow saccades (Bürk et al., 1996) and, in some individuals,
ophthalmoparesis (Lastres-Becker et al., 2008b; Pulst, 2015).
The symptoms are commonly triggered in the fourth decade
of life in an affected individual and they tend to worsen in a
progressive manner until the death of the patient (typically from
respiratory failure), which usually occurs within 21–25 years
after the onset of the disease phenotype (Klockgether et al.,
1998; Lastres-Becker et al., 2008b). In most cases, the physical
manifestations come together with cognitive impairments like
fronto-executive dysfunction, altered short-termmemory, lack of
attention (Bürk et al., 2003), and psychological dysfunctions that
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end up in insomnia, depression, and suicidal impulses, as it was
first uncovered by Reynaldo-Armiñán (cited in Lastres-Becker
et al., 2008b). A more recent work by Lo et al. (2016) included
a follow-up of 64 SCA2 patients that revealed a strong prevalence
of clinically relevant depression (22% of all patients) and suicidal
ideation (almost 50%), similarly to other SCAs.
These symptoms are usually the result of a wide
neurodegenerative process, with a severe olivopontocerebellar
atrophy as its most striking characteristic, together with early
degeneration in the substantia nigra and basal ganglia (Estrada
et al., 1999). Other brain regions such as the cerebral frontal
lobes, brainstem, cranial nerves, and spinal cord also show
signs of degeneration (Estrada et al., 1999; Pang et al., 2002;
Ishida et al., 2011). Interestingly, in vivo brain MRI of 24 SCA2
patients has also revealed a significant atrophy of regions like the
pontine base, the middle cerebellar peduncles and the cerebellar
hemispheres, when compared with either healthy controls or
patients with SCA1 and Machado-Joseph disease (MJD/SCA3l;
Bürk et al., 1996).
At the cellular level, there is a severe reduction in the number
of cerebellar Purkinje cells (PCs) as well as its arborization
(Estrada et al., 1999; Rüb et al., 2013). The cells of the granular
layer of the cerebellum also suffer neuronal loss, together with
the brain stem and the substantia nigra, which might explain
the parkinsonism observed in some patients (Pulst, 2015).
This is a critical point, since SCA2 is the subtype of SCA
that is most commonly associated with levodopa-responsive
Parkinson’s disease (PD) and atypical parkinsonism worldwide
(Gwinn-Hardy et al., 2000; Shan et al., 2001; Park et al., 2015).
Also, recent studies have found degeneration in the striatum,
pallidum, and even the neocortex (Estrada et al., 1999; Seidel
et al., 2012). In addition to this, several groups have presented
compelling evidence for the existence of nuclear and cytoplasmic
inclusions, stained with anti-ataxin-2, anti-expanded PolyQ
(1C2) and anti-ubiquitin antibodies, similarly to what happens in
other polyQ diseases (Koyano et al., 1999; Pang et al., 2002; Ishida
et al., 2011). All in all, this overall degeneration in the brains of
SCA2 patients goes far beyond the purely cerebellar alterations
that its name might imply and it ends up affecting the whole
brain.
DISEASE MECHANISMS OF SCA2
The ATXN2 gene has 25 exons that encode for a protein with
1152 amino acid residues, when it possesses 22 glutamines
(Scoles et al., 2012) and no sequence similarity to other polyQ
proteins apart from the glutamine-rich domain (Magaña et al.,
2013). The expansion of this domain above the disease threshold
triggers a series of anomalies at the cellular level, presumably
several years before the onset of the symptoms. In the following
section, we summarize some of the proposed mechanisms for the
pathophysiology of SCA2, which are illustrated in Figure 1.
Aggregation
The aggregation of mutant polyQ proteins into cytoplasmic
and/or intranuclear inclusions in neurons is a hallmark of these
neurodegenerative diseases (Williams and Paulson, 2008; Bauer
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FIGURE 1 | Molecular mechanisms proposed to be involved in SCA2 pathogenesis. The anti-sense transcription of the ATXN2 gene gives origin to the
repeat-expanded ATXN2-AS, with the ability to form hairpin structures and induce toxicity. The sense transcription encodes to the polyQ-expanded ataxin-2 protein,
which assembles in insoluble, not always ubiquitinated cytoplasmic aggregates, and recruits other proteins like E3 ubiquitin ligases. Ultimately, the UPS might get
overburden, disturbing the neuronal protein turnover and engaging in aberrant proteolytic cleavage, with the formation of N-terminal PolyQ-containing toxic fragments.
Also, the mutated ataxin-2 decreases the ability of WT ataxin-2 to stabilize mRNAs and upregulate protein expression, resulting in transcriptional and translational
dysregulations. On the other hand, the expanded polyQ protein binds to receptors in the ER and promotes a significant increase in intracellular calcium and,
consequently, excitotoxicity, and enhanced LTD in cerebellar PCs. Finally, posttranslational modifications such as phosphorylation at specific residues might modulate
the toxicity of ataxin-2, and RAN translation can result in additional polyalanine and/or polyserine toxic proteins. Blue, solid line boxes represent well-studied disease
mechanisms, with extensive supporting evidence in SCA2. Black, dashed line boxes represent pathogenic mechanisms that are well established in other PolyQ
disorders like HD and other SCAs, but whose relevance to SCA2 is still unclear.
and Nukina, 2009; Takahashi et al., 2010). Nevertheless, the
actual contribution of these aggregates to neurodegeneration
has eluded the scientific community for many years, which
tried to disclose their role as either causal or protective for the
pathogenic process (Todd and Lim, 2013). Likewise, the mutant
ataxin-2 aggregation and its role in SCA2 pathophysiology is
also surrounded in controversy. A recent study tried to correlate
the two main types of aggregates—granular cytoplasmic staining
(GCS) and neuronal nuclear inclusions (NNI)—to the severity
in neurodegeneration, with some interesting results (Seidel et al.,
2016). Using post-mortem tissue from the brainstem of 5 SCA2
and 6 MJD patients, the authors found a significant positive
correlation between the presence of GCS and a more severe
neurodegeneration, while the NNI appeared to have a more
protective role, at least in the MJD cohort. Also, Koyano et al.
(2014) suggested that a cytoplasmic aggregation pattern of
mutant ataxin-2 is prevalent in early stages of SCA2, whereas
the presence of nuclear inclusions is related to a final stage.
According to these and other studies (Ueda et al., 2014), the
cytoplasmic ataxin-2 granules might be the first aggregated
species in SCA2, actively contributing to pathogenesis by
disrupting essential cell mechanisms. However, on an interesting
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note, the presence of aggregates in the cerebellar PCs remains
quite controversial, with only a few reports of non-ubiquitinated
cytoplasmic inclusions in mouse models (Huynh et al., 2000;
Damrath et al., 2012).
Protein Recycling and Proteolytic Cleavage
Degradation of misfolded proteins typically occurs through two
distinct pathways: the ubiquitin proteasome system (UPS) or
autophagy. The dysfunction of the protein recycling pathways
is a much debated topic in neurodegenerative diseases and has
been extensively reviewed elsewhere (Berke and Paulson, 2003;
Ross and Pickart, 2004; Matsuda and Tanaka, 2010; Takalo et al.,
2013; Fecto et al., 2014; Cortes and La Spada, 2015). In SCA2,
it was recently proven that mutant ataxin-2 can be selectively
downregulated by FBXW8 (a subunit of an ubiquitin ligase
complex), and that both FBXW8 and PARK2 (E3 ubiquitin
ligase) are recruited to mutant ataxin-2 aggregates in cellular and
animal models (Damrath et al., 2012; Halbach et al., 2015). This
suggests a possible impairment in the UPS which, if perpetuated,
might result in toxicity and neurodegeneration. The malfunction
of the UPS can also result in increased cleavage of mutant
proteins into smaller, more toxic fragments, which have been
implicated in the pathogenesis of diverse neurodegenerative
traits involving abnormal protein accumulation (Li et al., 2010;
Matos et al., 2017). In SCA2, the artificial inhibition of the
UPS originated a 70 KDa fragment in cells transfected with
mutant ataxin-2, but not in those transfected with the WT form.
Also, a 42KDa fragment was detected in human post-mortem
brain samples, reactive to the polyQ-specific 1C2 antibody
(Huynh et al., 2000; Turnbull et al., 2004). Interestingly, this
fragment (presumably N-terminal, given the position of the
polyQ region) was detected both in a SCA2 patient and a cellular
model of the disease, but not in control samples. This might
suggest a link between mutant ataxin-2 proteolytic cleavage and
SCA2 pathogenesis.
Transcriptional and Translational
Dysregulation
The most studied function of ataxin-2 is the regulation of
translation and mRNA metabolism, as the very first efforts
to characterize this protein accumulated compelling evidence
toward this hypothesis. In fact, the first studies in yeast
successively identified direct interactors of ataxin-2, like the
poly(A)-binding protein 1 (PABP1) and the ataxin-2-binding
protein 1 (A2BP1 or RBFOX1), that are known regulators of
RNAmetabolism (Mangus et al., 1998; Shibata et al., 2000). Since
then, ataxin-2 has been shown to primarily localize in the Golgi
apparatus (Huynh et al., 2003) and the endoplasmic reticulum
(ER; van de Loo et al., 2009) and demonstrated to bind directly to
the 3′UTRs of mRNAs, promoting their stability (Yokoshi et al.,
2014). More importantly, these studies provided evidence that
the PolyQ-expanded ataxin-2 caused cell death by disrupting the
Golgi complex (Huynh et al., 2003) and actively downregulated
the stabilizing effect ofWT ataxin-2 in a PolyQ-length-dependent
manner, decreasing its ability to upregulate protein expression
(Yokoshi et al., 2014). So, in the global context of the disease, the
expanded polyQ tract can affect the protein turnover of the cell,
through a dysregulation of both synthesis (transcriptional and
translational dysfunction) and degradation (UPS impairment).
Considering the highly specialized and regulated functions of
establishing and maintaining synaptic activity, neurons are
particularly susceptible to alterations in protein turnover, which
apparently happen in SCA2. This crucial role of WT ataxin-2
in maintaining mRNA stability and regulating translation might
also explain the reason for ataxin-2 being associated with several
other neurodegenerative diseases like ALS, SCA1, and MJD
(Uchihara et al., 2001; Al-Ramahi et al., 2007; Lessing and Bonini,
2008; Elden et al., 2010; Nóbrega et al., 2015).
Calcium Dysregulation
The dysregulation of calcium signaling is found inmany different
neurodegenerative traits, and its role in the pathophysiology
of these disorders has been the subject of many extensive
reviews (Chopra and Shakkottai, 2014; Egorova et al., 2015;
Meera et al., 2016). In SCA2 research, there is compelling
evidence of abnormal calcium signaling, to which the PCs seem
to be particularly susceptible, triggering the very first physical
symptoms of the disease (Kasumu and Bezprozvanny, 2012).
Indeed, in 2005 it was first reported that long, normal CAG
repeats in the calcium voltage-gated channel subunit alpha 1A
(CACNA1A) correlates with an earlier onset of symptoms in
SCA2 patients (Pulst et al., 2005). Also, not only does ataxin-
2 co-localize with the ER, which is the largest depository of
intracellular calcium (van de Loo et al., 2009) but its mutated,
expanded form binds to the C-terminal of the type 1 inositol
1,4,5-trisphosphate receptor (InsP3R1; Liu et al., 2009). This
interaction significantly increases the release of intracellular
calcium in primary PCs cultures from a SCA2 transgenic
mouse model, and increases their sensitivity to glutamate-
induced cell death (Liu et al., 2009). Interestingly, several in vivo
experiments that targeted the activity of intracellular calcium
receptors and calcium-activated potassium receptors alleviated
many of the symptoms of these mice, establishing calcium
dysregulation as a major mechanism of PC degeneration in SCA2
(Kasumu et al., 2012a,b; Liu et al., 2009). Finally, Kasumu and
Bezprozvanny proposed that the increase in intracellular calcium
mediated by expanded ataxin-2 intensifies cerebellar long-term
depression (LTD) in an attempt to control excitotoxicity, which
in turn triggers the first manifestations of ataxia (Kasumu
and Bezprozvanny, 2012). A similar calcium dysregulation
mechanism based on the same InsP3R1 receptor has also been
proposed for HD and MJD, two of the most common polyQ
disorders, suggesting that it might be a transversal mechanism
in this group of diseases (Tang et al., 2003; Chen et al., 2008).
RNA Toxicity
For several years, themain focus of research in polyQ diseases has
been the expanded polyQ tract of the affected proteins, and the
different toxic effects that it exerts in neurons. However, recent
studies have highlighted the contribution of non-coding RNA
molecules, such as anti-sense and long non-coding transcripts,
to the pathophysiology of polyQ and other neurodegenerative
disorders (Moseley et al., 2006; Ladd et al., 2007; de Mezer et al.,
2011). The mechanisms of RNA toxicity in neurodegeneration
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have been extensively reviewed elsewhere (Johnson et al., 2012;
Salta and De Strooper, 2012; Tan et al., 2012) and include
the sequestration of RNA-binding proteins, the production of
mutant repeat RNAmolecules by anti-sense transcription and the
modulation of mutated genes by miRNAs. In SCA2, bidirectional
transcription of theATXN2 gene has been recently reported, with
the production of a neurotoxic anti-sense transcript (ATXN2-AS)
as a consequence (Li et al., 2016). The supporting evidence is very
robust, with the expanded CUG-repeat RNA being detected in
the post-mortem cerebellum and cortex of SCA2 patients, human
fibroblasts, human induced pluripotent stem cells (iPSCs),
a BAC-transgenic mouse model and a lymphoblastoid cell
line. Moreover, the transfection with non-translatable mutant
ATXN2-AS, but not the WT ATXN2-AS, induced toxicity in SK-
M-NC cells and primary mouse cortical neurons, presumably
from the CUG-repeat tendency to form RNA hairpin structures
(Li et al., 2016).
Alternative Disease Mechanisms
The previously described mechanisms have substantial evidence
to support their role in the pathophysiology of SCA2. However,
other disease pathways have been well established for PolyQ
diseases, including other SCAs, that are also worthy of
mention despite their link to SCA2 remaining unclear. In
fact, many different studies showed that phosphorylation and
other posttranslational modifications of polyQ proteins might be
implicated in different aspects of pathogenesis, either decreasing
or enhancing neurodegeneration in HD, SCA1, and MJD
(Humbert et al., 2002; Chen et al., 2003; Emamian et al., 2003;
Luo et al., 2005; Pennuto et al., 2009; Warby et al., 2009; Matos
et al., 2016). In SCA2, Turnbull and colleagues reported that
ataxin-2 is indeed phosphorylated in SY5Y cells, presumably
at the RXXSXP motif, similarly to ataxin-1 (Turnbull et al.,
2004). Nevertheless, the impact of this modification in the
disease pathogenesis remains elusive. Finally, a new mechanism
for neurodegeneration was observed in SCA8, where it was
found that a non-ATG-translation (RAN) of the CAG expansion
resulted in polyserine and polyalanine proteins, apart from the
polyQ protein (Zu et al., 2011). This work has caused a turmoil
in the field of DNA repeat expansions disorders, with new non-
ATG proteins being reported in several neurodegenerative traits,
rendering the field far more complex than it was first considered
(Cleary and Ranum, 2014). In SCA2, this phenomenon was also
observed for the ATXN2 gene, although in lower levels compared
to canonical ATG translation and the study failed to detect
polyserine and polyalanine proteins (Scoles et al., 2015).
SCA2 MOUSE MODELS
During the last two decades, a number of cellular and animal
models of SCA2 have been developed to greatly contribute to
our understanding of this disease. Indeed, although they are
not the focus of this work, simple models like yeast, C. elegans
and D. melanogaster were among the very first models used
and have been crucial to infer on the ubiquitous functions
of ataxin-2, such as: the embryonic development (Kiehl et al.,
2000; Ciosk et al., 2004); the translation regulation and mRNA
metabolism (Mangus et al., 1998; Satterfield and Pallanck, 2006);
the regulation of circadian rhythms (Lim andAllada, 2013; Zhang
et al., 2013); and modulating the formation of stress granules
(Ralser et al., 2005). Likewise, the creation and characterization
of two murine KO models of ATXN2 have provided precious
new insights into the functions and pathways of this protein
(Kiehl et al., 2006; Lastres-Becker et al., 2008a; Huynh et al.,
2009; Fittschen et al., 2015; Halbach et al., 2016; Meierhofer
et al., 2016) including a putative role in insulin resistance
and obesity, which was validated in humans through Genome-
wide association studies (Auburger et al., 2014). Finally, the
development of iPSCs lines from SCA2 patients was recently
reported, as well as CRISPR-Cas9 corrected isogenic iPSCs,
to serve as suitable controls. These lines represent a unique
opportunity to study the SCA2 disease mechanisms from actual
patient-derived neurons (Xia et al., 2013; Marthaler et al.,
2016a,b).
The purpose of this work is to present a comprehensive
review on 5 mouse models of SCA2 that present behavioral
characteristics resembling the human condition. In fact, the
existing therapies for SCA2 rely basically on palliative care and
non-specific medication to alleviate the major symptoms, which
is inefficient to halt the disease progression. Thereby, in the
last two decades, several authors created transgenic and Knock-
in mice with the purpose of testing more effective therapeutic
strategies that might be translated into the clinic. We aim
to describe and compare each one of these models on the
basis of their motor impairments, neuropathology and age of
onset, and provide sustained examples of their usefulness in
subsequent studies. To the best of our knowledge, this type
of work has not been made for SCA2 and thereby it will
constitute a valuable and important tool for researchers to
choose the most adequate model addressing different scientific
questions.
The following models will be discussed chronologically
according to their publication year, consisting of 4 transgenic and
1 Knock-in (KI) mice: Q58 (Huynh et al., 2000); Q75 (Aguiar
et al., 2006); Q42KI (Damrath et al., 2012); Q127 (Hansen et al.,
2013); BAC-Q72 (Dansithong et al., 2015).
Q58
This is the first report of a mouse model of SCA2, where the
authors created a transgenic line that expresses a full length
version of the human ATXN2, with 58 CAGs (Huynh et al.,
2000). This mutant gene is regulated by a heterologous promoter
(Purkinje cell protein 2—Pcp2) that directs the expression of the
transgene to the PCs of the mice. The authors used the hybrid
B6D2F1 as the genetic background for both the model and the
control group, which expresses the cDNA of the human ataxin-
2 with 22 glutamines (Q22). The most characterized mouse line
was the Q58–11, which incorporated three copies of the human
transgene, contrary to the Q22 lines, with just one copy.
The mice expressing the mutant ATXN2 exhibited clasping
at 32 weeks of age, contrary to the control group (Q22). Also,
the same animals showed a 19% reduction in the stride length
at 16 weeks of age, when compared with the control and
Frontiers in Neuroscience | www.frontiersin.org 5 December 2016 | Volume 10 | Article 572
Alves-Cruzeiro et al. Mouse Models of Spinocerebellar Ataxia Type 2
the WT. Likewise, the rotarod test showed a significant worse
performance for the homozygous Q58 when comparing with the
control group and the WT, with a smaller latency to fall (around
50%) at 16 weeks of age. These motor deficits were progressive,
with both the homozygous and the heterozygous Q58 showing
severe impairment at 26 weeks of age. There were no differences
detected between the Q22 lines and the WT, in any of the tests.
In a subsequent characterization done by Liu and co-workers
(Liu et al., 2009), a general lack of balance and coordination
was reported in the Q58 mice, as measured by the beamwalk
test, when comparing with WT mice. These differences became
significant at 32 weeks of age, including longer latencies to cross
the beam and an increased number of foot slips, which worsened
in a progressive manner with aging (Table 1).
The neuropathology in this model showed a decrease in the
immunoreactivity with Calbindin-28K—a marker for neuronal
dysfunction—at 4 weeks of age for the homozygous Q58.
Similarly to the motor dysfunction, the loss of Calbindin-28K
was progressive and worsened from 7 to 14 weeks. At 24–27
weeks of age, the authors also detected a significant loss of 50%
in the number of PCs in the mutant lines, contrasting with the
control lines that showed no signs of neuropathology at any
time point. In a different work (Kasumu et al., 2012b), the Q58
transgenic mice were further characterized and an abnormal
electrophysiological profile of these cells was reported at 24
weeks, worsening in a progressive manner with aging. This
profile includes a decrease in the number of firing PCs and a
reduced firing frequency of PCs in SCA2 mice, when compared
with the WT (Table 2).
Q75
Another model was developed in 2006, when Aguiar et al.
(2006) used the same methodology of pronuclear microinjection
to create a mouse model with a human full-length version of
ATXN2. The human gene was isolated from a Cuban patient with
75 CAG using RT-PCR and obtaining an amplicon of 4.477Kb
corresponding to the cDNA of the ataxin-2 isoform 1. This
transgene was then expressed in the transgenic model under
the regulation of the self-human SCA2 promoter. This approach
allowed to obtain ubiquitous expression of the transgene across
the entire body of the animal, as it was detected at the transcript
level in the lungs, kidney, muscle tissue, brain and liver, and
at the protein level in the cerebellum. The authors used the
mouse hybrid strain B6D2F1 X OF1 as the genetic background
for this model, and as a control strain for the behavioral tests, WT
littermates. F066, that integrated one or two copies of the SCA2
transgene, was the most characterized line.
An ataxic behavior was observed in the Q75 mice when
subjected to the rotarod assay. Indeed, a significant worse
performance by the heterozygous transgenic animals was
observed at 12 weeks, and by the homozygous at 6 weeks of age,
when compared with the WT (Table 1).
Interestingly, the neuropathology revealed that, despite the
ubiquitous expression throughout the body, only degeneration
of PCs is reported, suggesting a somewhat targeted effect
(Table 2).
Q42KI
In 2012 it was published the first and only report so far of a
knock-in mouse model of SCA2 (Damrath et al., 2012). In this
work, Damrath and colleagues used the basic concept of the
homologous recombination in embryonic stem cells to replace
the normal murine atxn2 gene with a mutagenized version with
42 CAG repeats. This mutant form is under the control of
the endogenous murine atxn2 promoter and was transmitted
stably to the progeny for over nine consecutive generations.
Moreover, the gene product was detected in the cortex and
cerebellum at the transcript and protein level, demonstrating that
the CAG expansion does not impair the atxn2 transcription and
translation. The C57BL/6 mice strain was used as the genetic
background and the WT littermates served as the controls for
behavioral and neuropathological analysis.
By analyzing the phenotype of these Knock-ins, two
interesting conclusions were drawn. First, as early as 1 week
of age was enough to detect a significant 19% reduction in the
weight of these animals as compared with the WT, a difference
that remained for their entire life. Secondly, the mutant mice
exhibited a very mild ataxic behavior: no differences were found
in the open field, grip or footprint analysis between the Knock-
ins and the WT. As for the accelerating rotarod, the differences
became significant only at 72 weeks of age, for the homozygous
mice (Table 1). On its turn, the heterozygous did not show any
impairment at all when compared with theWT, at any time point
analyzed.
TABLE 1 | Behavioral analysis of SCA2 mouse models.
Mouse Reduced body Onset Impairments Onset Anomalies Onset Clasping Onset Impairments in Onset
model weight (weeks) in rotarod (weeks) in footprint (weeks) (weeks) the beamwalk (weeks)
Q58 NA Yes 16 Yes 16 Yes 32 Yes 32
Q75 NA Yes 6 NA NA NA
Q42KI Yes 1 Yes 72 NE NA NA
Q127 NA Yes 8 NA NA NA
BAC-Q72 Yes 8 Yes 16 NA NA NA
Behavioral hallmarks of the mouse models of SCA2. For each model, the symptoms/characteristics are included as existent (“Yes”), non-existent (“NE”), or Not available (“NA”), with the
corresponding age of onset.
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TABLE 2 | Neuropathology of SCA2 mouse models.
Model Neurodegeneration Onset Neuronal Onset Ataxin-2 Onset Morphological Onset Electrophysiological Onset
(weeks) loss (weeks) aggregates (weeks) alterations (weeks) dysfunctions (weeks)
Q58 Loss of calbindin-28K
immunoreactivity
4 Decreased
PCs number
24 No NIs.
Cytoplasmic
microaggregates
NA Decrease in the number
of firing PCs
24
Reduced firing
frequency of PCs
Q75 Loss of calbindin-28K
immunoreactivity
52 NA NA Loss of dendrites in
PCs. Shrinkage of cell
bodies in PCs
52 NA
Q42KI NE NE No NIs.
Cytoplasmic
insoluble
aggregates
56 NA NA
Q127 NA Decreased
PCs number
40 Perinuclear
aggregates
4 Loss of molecular layer
thickness
12 Slower firing frequency
of PCs
6
BAC-Q72 Loss of calbindin-28K
immunoreactivity
24 NE NA Shrinkage of dendritic
trees in PCs
NA
Neuropathological hallmarks of the mouse models of SCA2. For each model, a small description of its neuropathology and the corresponding age of onset is provided. NIs, Nuclear
inclusions; NA, Not available; NE, Non-existent.
The neuropathological assessment also revealed very mild and
late-onset alterations, consistent with the behavioral results. In
fact, the only perceptible alterations were cytoplasmic ataxin-
2-containing insoluble aggregates, identified in the PCs of the
Knock-in mice. These aggregates first became detectable at 56
weeks of age, and then at 96 weeks inmuch higher number. There
were no signs of neuronal loss, neurodegeneration or nuclear
inclusion bodies (Table 2).
Q127
Another transgenic mouse model was created in Hansen et al.
(2013) with a slightly different objective and thereby a distinct
approach. The purpose was to evaluate the electrophysiological
and gene expression changes in PCs in SCA2, and to correlate
those variations with the onset of the motor phenotype. With this
objective in mind, Hansen and co-workers created a model mice
with 127 CAG repeats under the Pcp2 promoter to try and obtain
a strong and targeted degeneration in the PCs as well as a robust
ataxic phenotype. The authors used the mouse strain B6D2F1 as
the genetic background for this model and, as a control strain for
the behavioral tests, WT littermates were used.
As early as 8 weeks was enough to show a motor dysfunction
in the accelerating rotarod in the transgenic mice, which
worsened in a progressive manner until 36 weeks of age. By this
time point, the latency to fall of the mutant animals showed
a significant reduction of 50% when compared with the WT
littermates (Table 1).
The neuropathology of the Q127 mice was also altered, with
the presence of ataxin-2 aggregates in the PCs at 4 weeks,
and increasing in number in subsequent time points. Another
important feature was the decrease in the molecular layer
thickness, which became significant at 12 weeks of age and
progressively aggravated, becoming over 60% reduced comparing
with the WT littermates. Neuronal loss was also observed in
the transgenic animals, at 40 weeks of age, with a reduction in
the number of PCs. Finally, the electrophysiological profile of
these cells also showed differences in the mutant animals, namely
a slower firing frequency that was significant at 6 weeks and
worsened with age (Table 2).
BAC-Q72
Finally, in 2015, Dansithong and co-workers developed the
most recent transgenic mouse model of SCA2 available, with
72 CAG repeats (Dansithong et al., 2015). This model was
created with Bacterial Artificial Chromosomes (BAC), which
are DNA constructs based on a functional fertility plasmid
(or F-plasmid). In recent years, these large-insert DNA clones
have been used to create transgenic animals mainly due to its
capacity to include an entire gene sequence, including non-
coding regions (Heintz, 2001; Van Keuren et al., 2009). As
for the genetic background, the authors used the FVB mouse
strain for both the model and the control group, which contains
the entire gene of the human ATXN2 with 22 CAGs (BAC-
Q22). Also, the BAC-Q72 and the BAC-Q22 integrated 4 and
10 copies of the corresponding transgenes, respectively, and
they are both regulated by the endogenous human promoter. In
conclusion, this strategy allowed obtaining ubiquitous expression
of the transgenes across the entire body of the animal, as it
was detected at the transcript level in the heart, liver, and
the entire central nervous system and at the protein level in
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the cerebellum. The most characterized mutant line was the
BAC-ATXN2-Q72.
Similarly to the Q42KI, both the BAC-Q72 and the BAC-Q22
also weighted significantly less than the WT, starting at 8 weeks
of age and progressing until a 30% reduction when comparing
to the WT littermates. The transgenic with the mutant ataxin-
2 suffered impairments in the motor coordination, showing a
decreased latency to fall in the accelerating rotatod, which started
at 16 weeks of age and progressively worsened until the 36 weeks
(Table 1).
The neuropathological analysis also showed dysfunctions
in these BAC-Q72 mice, at 24 weeks, with shrinking of PCs
dendritic trees and loss of the calbindin and Pcp2 proteins in the
cerebellum (Table 2).
DISCUSSION
The development of mouse models that mimic the SCA2
phenotype was needed to: (a) facilitate the testing of new
therapeutic strategies, and (b) allow the study of the disease
progression in an animal that is biologically close to humans.
So far, 5 different mouse models have been created that
assume behavioral signs/symptoms found in human patients.
Considering the number and severity of the symptoms, their
age of onset, the neuropathological progression and the design
strategy itself, each one of these models can prove to be quite
useful when addressing different scientific questions. In Table 3,
we summarized the key features of each mice that we consider to
be either advantageous or not for different researching purposes,
putting together a global view of the available murine models of
SCA2.
The Q58 transgenic mice have a very well characterized and
progressive ataxic phenotype and neuropathology as its greatest
advantage. In fact, these mice exhibit not only a strong motor
impairment in the rotarod, but they are also the only described
model with anomalies in the footprint, beamwalk and clasping
when comparing with a control Q22 group (Table 1). These
behavioral tests are commonly considered by experts (Brooks and
Dunnett, 2009) to be strong indicators of motor incoordination,
lack of balance and an abnormal gait, which are key features
of the cerebellar ataxia described in human SCA2 patients
(Pulst, 2015). Besides that, they have a marked neuropathological
phenotype, with clear signs of neuronal dysfunction, neuronal
loss and cytoplasmic polyQ aggregates in PCs, all of which
were corroborated in post-mortem human tissue (Estrada et al.,
1999; Koyano et al., 1999; Huynh et al., 2000; Ishida et al.,
TABLE 3 | The major advantages and downsides of SCA2 mouse models.
Mouse models Representative line Advantages Disadvantages
Q58 Q58-11 Robust, well-characterized behavioral impairments and
neuropathology;
Unable to study other brain regions: targeted expression
to PCs;
Suitable to study PCs dysfunction; Non-physiological expression levels of
ataxin-2—overexpression;
Practical for research into new therapeutic strategies; Pronuclear injection: random integration;
Q75 F066 Ubiquitous expression of mutant ataxin-2; Pronuclear injection: random integration;
Integrated only 1 or 2 copies of the transgene; Lack of control transgenic line;
Early onset of symptoms and robust motor
impairment—practical in testing for new therapies;
No other symptom besides motor incoordination;
Q42 KI CAG42 Very faithful to the human condition in terms of
physiological expression levels and age of onset;
Mild ataxia phenotype and neuropathology with late
onset of symptoms;
Ideal to study early differential gene expression levels; Unpractical for testing new therapies that alleviate
symptoms;
Potential to find disease biomarkers;
Targeted insertion;
Q127 ATXN2Q127 Very robust impairments in behavior and neuropathology
with early onset of symptoms;
Unable to study other brain regions: targeted expression
to PCs;
Suitable to study electrophysiological dysfunctions in PCs
and testing new therapies;
Decreased faithfulness to the human disease;
Pronuclear injection: random integration;
BAC-Q72 BAC-ATXN2-Q72 The entire gene (introns included) was inserted into the
mouse genome: suitable to study RNA-related
mechanisms;
No other symptoms besides motor incoordination;
Ubiquitous expression of mutant ataxin-2; Mild neuropathology;
The major advantages and disadvantages of SCA2 mouse models. For each mutant mouse line, the most notorious upsides and downsides are given to facilitate the choice of the
most adequate model addressing different biological questions.
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2011). Interestingly, electrophysiological impairments in Q58
PCs have also been reported, nearly concomitant with the
onset of behavioral anomalies, suggesting that the burst firing
of these neurons is directly linked with the ataxic symptoms
(Kasumu et al., 2012b). These behavioral and neuropathological
traits are common to several SCAs, as it was evidenced by
similar results in mouse models of SCA1 (Burright et al., 1995),
MJD (Chou et al., 2008; Torashima et al., 2008), or SCA7
(Garden et al., 2002). The diversity of the Q58 phenotype and
its extensive characterization make this mouse model quite
practical to study the effect of new therapeutic strategies in
different aspects of the SCA2 phenotype, as it was demonstrated
already by some interesting works: Liu et al. (2009) treated the
Q58 mice with a pharmacological inhibitor of the Ryanodine
receptor, successfully improving the performance of the mutant
animals in the beamwalk and the rotarod, and establishing
this receptor as a potential therapeutic target for SCA2; Chang
et al. (2011), rescued some of the Q58 motor symptoms by
injecting these mice intravenously with human mesenchymal
stem cells; Kasumu et al. (2012a) used a selective modulator of
the SK2/3 channels, administered orally, to alleviate the motor
dysfunctions of this model, achieving a significant improvement
in the beamwalk and accelerated rotarod; on a different work,
Kasumu et al. (2012b) relied on a phosphatase, delivered
by adeno-associated viruses, to inhibit the 1,4,5-triphosphate
receptor-mediated calcium release. This strategy was successful
in preventing the PC dysfunction and rescuing some of themotor
impairments of transgenic mice. Nevertheless, there are some
issues worth of notice in this model. First, it uses a heterologous
promoter that, unlike the human patients that have expression
of mutant ATXN2 across the whole body, directs the expression
exclusively to the PCs. This feature, although useful for the
study of cerebellar dysfunctions like protein aggregation in PCs,
hamper the analysis of other brain regions and non-cerebellar
symptoms such as Parkinsonism and ALS-related degeneration
of motor neurons (Shan et al., 2001; Furtado et al., 2004; Elden
et al., 2010). Second, the method of pronuclear injection by
which this model was generated results in the integration of the
transgene in a random location of the genome, which might
be disrupting the function of endogenous genes. Finally, the
three Q58 founder mice integrated two, three or four copies
of the transgene, leading to non-physiological levels of ataxin-2
expression.
Unlike the Q58, the Q75 model exhibits expression of the
transgene across the whole body, as it was detected at the
transcript level in the lungs, kidney, brain, liver, and skeletal
muscle of the mice, and at the protein level in the cerebellum.
This renders the model more faithful to the human condition,
since ataxin-2 is ubiquitously expressed throughout the entire
human body (Imbert et al., 1996; Pulst et al., 1996; Sanpei et al.,
1996). This feature should allow to study different brain regions
and their contributions to the pathophysiology of the disease,
although no reports were found of such studies. Moreover, the
transgenic mice display a severe motor impairment, with an
earlier onset of those symptoms than any other model, which
makes them less expensive and time-consuming to test new
therapies and evaluate its effect in an ataxic phenotype. Themajor
disadvantages lie with the method of pronuclear injection that
promotes random integration, and also to the lack of a transgenic
animal line with wild-type ATXN2, to serve as a suitable control.
Although the motor incoordination is quite severe, there is no
information available of any other motor behavior (Table 1) and
the neuropathology is not as well-characterized as in the Q127 or
in the Q58 (Table 2).
Contrasting with every other model, the Q42KI mice present
a faint and late-onset phenotype, probably due to the reduced
number of CAGs. Indeed, although these mice display a reduced
body weight starting in the first week of age, the behavioral
symptoms appear at 72 weeks, with a mild impairment in motor
coordination, and only for the homozygous animals (Table 1).
Likewise, the only neuropathological hallmarks detected were
the presence of cytoplasmic ataxin-2 aggregates, at 56 weeks
(Table 2). An early-onset and fast-progressive ataxia are usually
preferable when testing new therapeutic strategies or drugs, for
which reason the Q42KI are impractical for this purpose. Also,
the heterozygous Q42KI did not show any motor impairments
when compared with the WT, contrary to what happens in
human SCA2 patients. Notwithstanding this, the faithfulness
of these mice to the human condition is unparalleled by any
other model available: physiological levels of expression, targeted
insertion, and a late onset of the symptoms. In fact, transgenic
mice represent an overexpression paradigm that explains the
earlier onset and severer phenotype, but their modeling is limited
to the very last stages of SCA2, disregarding the long pre-
symptomatic stage of the human condition. Thereby, the Q42KI
surges as the best model to study the early molecular mechanisms
involved in the pathology of SCA2. The authors of this work
did exactly that, by performing a genome-wide transcriptomic
analysis in the cerebellum, brain stem, and liver of the Knock-in
and the WT mice, and identifying one gene—Cyp4a14, involved
in cholesterol biosynthesis—differentially expressed in the liver
at 24 weeks of age. In a subsequent study, Halbach et al. (2016)
investigated the cerebellar transcriptome of these Q42KI, finding
downregulated expression levels of two genes involved in calcium
homeostasis: Atp2a2 and Itpr1, which were also downregulated
in SCA2 KO mice (Lastres-Becker et al., 2008a). These works
might pave the way to identify new disease biomarkers and also
strengthen the hypothesis that deranged calcium signaling is a
key mechanism in the PCs degeneration found in the transgenic
models (Liu et al., 2009).
The Q127 transgenic shows a very robust, early-onset, and
well-characterized phenotype. Indeed, the expression of ATXN2
containing a high number of CAG repeats with a PC-specific
promoter allowed to obtain a severe dysfunction in the motor
coordination of these mice, which can be observed as early as at
8 weeks of age. Likewise, several aspects of the neuropathology
have been well studied, with a significant decrease in the number
of PCs, perinuclear aggregates and a decrease in the molecular
layer thickness, assembling a range of features that are frequently
found in human patient’s data (Estrada et al., 1999; Koyano
et al., 1999; Huynh et al., 2000). Furthermore, the diversity
of the phenotype and its early-onset make this model quite
practical for testing new therapeutic strategies and assessing its
effect in ataxia. The Q127 mice also offer a good opportunity
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to study the SCA2-related neuronal dysfunction of PCs with
more detail, as the authors reported severe anomalies in the
electrophysiological profile of these cells, with a 75% reduction
in the firing frequency compared to WT mice. The biggest
disadvantage of this model, to our understanding, lies with
aspects that confer a lower biological relevance when comparing
with the Q42KI or the BAC-Q72. Indeed, the most frequent
disease alleles of SCA2 contain between 37 and 41 CAG repeats
(Geschwind et al., 1997; Pulst, 2015) with only exceptional cases
reporting >100 CAG repeat alleles (Babovic-Vuksanovic et al.,
1998; Paciorkowski et al., 2011). Together with the targeted
expression to the PCs, these transgenic mice are not as faithful
to the human condition and actually model a very late stage
of SCA2. The likely insertional mutagenesis derived from the
method of pronuclear injection and the lack of a transgenic
animal line with wild-type ATXN2, to serve as a suitable control,
might also be considered as downsides to this model.
Finally, the most recent transgenic model of SCA2 presents
a new approach, which is the use of the Bacterial Artificial
Chromosomes to insert the mutant ATXN2 transgene. This
strategy has been used to create some very robust models of
disease (Gray et al., 2008; Li et al., 2009) and its advantages
include the insertion of the entire gene sequence into the
host genome. This feature allows to study the contribution of
normal splicing events and the regulation by non-coding regions
of ATXN2 to the pathophysiology of the disease, as recently
demonstrated by Li et al. (2016). In this work, the authors
successfully identified the ATXN2-AS transcript in cortex and
cerebellum of the BAC-Q72, a non-coding and expanded RNA
with toxic properties whose expression was corroborated in
numerous sources of human samples. This would have been
impossible in any other transgenic mouse model that uses
cDNA to express the mutant ataxin-2. In fact, considering
the increasing relevance given to RNA-related mechanisms of
toxicity in neurodegenerative diseases, the BAC-Q72 is the
most adequate model to study these phenomena in SCA2
(Johnson et al., 2012; Tan et al., 2012; Cleary and Ranum, 2013;
Ramaswami et al., 2013). Besides this, the mice also displayed a
moderate ataxic phenotype at 16 weeks, with impairments in the
accelerated rotarod, which worsened in a progressive manner. As
disadvantages, we refer to the mild neuropathology, consisting
in a slight dysfunction of PCs, which make it less appealing to
evaluate the effect of potential therapies in disease progression.
To summarize, all the mouse models of SCA2 have advantages
and disadvantages, but they have all proven very useful to
the understanding of this terrible neurodegenerative condition.
Indeed, the Q42KI allows studying the very early molecular
mechanisms of pathogenesis with the potential to identify new
disease biomarkers, while the transgenic models (Q58, Q75,
and Q127) might lack some physiological relevance, but possess
robust phenotypes and early onset of symptoms. This makes
them highly practical for testing new therapeutic strategies,
allowing its assessment in various aspects of behavior and
neuropathology in a less expensive and time-consuming manner.
Finally, the most recent transgenic mice (BAC-Q72) show
promise in studying new emerging RNA-related mechanisms of
SCA2 pathology. On a final note, ATXN2 has been shown to
take part in various other neurodegenerative diseases besides
SCA2, such as ALS, SCA1, MJD, and PD, revealing an intrinsic
cascade of pathways regulated by this gene (Al-Ramahi et al.,
2007; Lessing and Bonini, 2008; Elden et al., 2010; Nóbrega et al.,
2015; Nkiliza et al., 2016; Sen et al., 2016). The available mouse
models of SCA2 are insufficient to explore these new lines of
research, highlighting the urgency of developing new ones that
model the neurodegeneration of dopaminergicmidbrain neurons
and motor neurons, affected in PD and ALS.
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